Loading…
Biliary carcinoembryonic antigen in the diagnosis of occult hepatic metastases from colorectal cancer
Background and Objectives Twenty five percent of patients who undergo radical surgical treatment for colorectal cancer have occult hepatic metastases that become evident during the follow‐up period. We evaluated whether biliary carcinoembryonic antigen (CEA) measurements could be used in these patie...
Saved in:
Published in: | Journal of surgical oncology 2002-09, Vol.81 (1), p.8-11 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background and Objectives
Twenty five percent of patients who undergo radical surgical treatment for colorectal cancer have occult hepatic metastases that become evident during the follow‐up period. We evaluated whether biliary carcinoembryonic antigen (CEA) measurements could be used in these patients to diagnose occult hepatic metastases.
Methods
Three groups of patients were enrolled in the study. The first group consisted of patients treated for lithiasis of the common bile duct, the second group was affected by colorectal cancer and evident hepatic metastases, and the third group of patients underwent radical surgical treatment for colorectal cancer but had no evident hepatic metastases.
Results
In the first study group, mean biliary CEA level was 0.52 ng/mL (normal value: 0–5 ng/mL) (diagnostic accuracy: 100%), 83.3 ng/mL in the second group (diagnostic accuracy: 91%) and 3.9 ng/mL in the third group. We registered only one false‐positive result in the third group, whereas biliary CEA level was above normal values in the three patients in whom hepatic metastases developed (diagnostic accuracy: 89.5%).
Conclusions
This study suggests that biliary CEA determination could represent an important method to select patients affected by occult hepatic metastases for inclusion in appropriate treatment protocols. J. Surg. Oncol. 2002;81:8–11. © 2002 Wiley‐Liss, Inc. |
---|---|
ISSN: | 0022-4790 1096-9098 |
DOI: | 10.1002/jso.10143 |